Interestingly, Alessi et al. (2009) demonstrated that targeting bFGF may overcome anti-VEGF resistance; thus, anti-bFGF therapy is undergoing clinical trials as an antiangiogenic therapy for ovarian cancer (Burger 2011). Here, VEGFA is linked to ovarian carcinoma.